MARKET

CVM

CVM

CEL SCI
AMEX

Real-time Quotes | Nasdaq Last Sale

11.15
-1.01
-8.31%
Closed 17:42 09/20 EDT
OPEN
11.56
PREV CLOSE
12.16
HIGH
11.76
LOW
11.12
VOLUME
692.87K
TURNOVER
--
52 WEEK HIGH
40.91
52 WEEK LOW
7.08
MARKET CAP
479.76M
P/E (TTM)
-12.9923
1D
5D
1M
3M
1Y
5Y
Cel-Sci Corporation Files For U.S. Patent Titled 'NOVEL PEPTIDES FOR VACCINATION AND TREATMENT OF 2019-nCoV INFECTIONS'
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=6592&p=132&f=G&l=50&d=PG01&S1=20210902.PD.&OS=PD/20210902&RS=PD/20210902
Benzinga · 09/02 13:58
CVM: Primum Non Nocere
By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT
Benzinga · 08/29 09:21
Mid-Day Market Update: monday.com Jumps Following Strong Q2 Results; Kubient Shares Plunge
Midway through trading Tuesday, the Dow traded down 0.81% to 35,336.88 while the NASDAQ fell 0.89% to 14,661.86. The S&P also fell, dropping 0.65% to 4,450.54.
Benzinga · 08/17 16:11
CEL-SCI Q3 EPS $(0.25) Up From $(0.27) YoY
CEL-SCI (AMEX:CVM) reported quarterly losses of $(0.25) per share. This is a 7.41 percent increase over losses of $(0.27) per share from the same period last year.
Benzinga · 08/16 13:07
Analyzing CEL-SCI's Unusual Options Activity
On Tuesday, shares of CEL-SCI (AMEX:CVM) saw unusual options activity. After the option alert, the stock price moved up to $9.22.
Benzinga · 08/10 14:49
Understanding CEL-SCI's Unusual Options Activity
CEL-SCI (AMEX:CVM) shares experienced unusual options activity on Monday. The stock price moved down to $7.68 following the option alert.
Benzinga · 07/19 16:41
Unusual Options Activity Insight: CEL-SCI
Shares of CEL-SCI (AMEX:CVM) saw some unusual options activity on Monday. Following the unusual option alert, the stock price moved up to $9.35.
Benzinga · 07/12 15:51
CVM: Data Has Been Released
By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT Data Readout From the IT MATTERS Trial On June 28, 2021, CEL-SCI Corporation (NYSE:CVM) reported selected data from the IT-MATTERS trial. While details for the primary endpoint were not p...
Zacks Small Cap Research · 07/08 16:16
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CVM. Analyze the recent business situations of CEL SCI through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CVM stock price target is 12.00 with a high estimate of 12.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 69
Institutional Holdings: 5.85M
% Owned: 13.60%
Shares Outstanding: 43.03M
TypeInstitutionsShares
Increased
19
2.66M
New
30
493.48K
Decreased
4
177.55K
Sold Out
3
243.82K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.35%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Chief Executive Officer/Director/Treasurer
Geert Kersten
Senior Vice President/Secretary
Patricia Prichep
Senior Vice President
John Cipriano
Senior Vice President
Daniel Zimmerman
Chief Scientific Officer
Eyal Talor
Independent Director
Bruno Baillavoine
Independent Director
Robert Watson
Independent Director
Peter Young
No Data
About CVM
CEL-SCI Corp is a clinical-stage biotechnology company. The Company is focused on activating the immune system to fight cancer and infectious diseases. The Company is engaged in research and developing the treatments for the cancer and other diseases by using the immune system. The Company’s lead investigational therapy Multikine (Leukocyte Interleukin, Injection) is in a pivotal Phase 3 clinical trial. Its Multikine is an investigational immunotherapy under development for the potential treatment of certain head and neck cancers. The Company using its Ligand Epitope Antigen Presentation System (LEAPS) technology platform is investigating product candidates include CEL-2000 and CEL-4000. CEL-2000 and CEL-4000, vaccine product candidates under development for treatment of rheumatoid arthritis. It is also investigating LEAPS COVID-19 conjugates as a potential treatment of coronavirus (COVID-19) in hospitalized and at-high-risk patients at the University of Georgia’s (UGA) Center.

Webull offers kinds of CEL-SCI Corporation stock information, including AMEX:CVM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CVM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CVM stock methods without spending real money on the virtual paper trading platform.